Icotrokinra

What is Icotrokinra?

Icotrokinra (development codes JNJ-77242113 and JNJ-2113; brand name Icotyde) is a 13-amino-acid peptide, closed into a ring by a disulfide bridge and built with several non-natural amino acids, that binds the interleukin-23 receptor (IL-23R) and stops the IL-23 cytokine from switching it on. Psoriasis is driven by high levels of immune signals including IL-23, which sits at the top of the IL-23/Th17 inflammatory pathway; blocking it lowers the downstream cytokines IL-17A, IL-17F and IL-22. The established IL-23 drugs, ustekinumab (Stelara), guselkumab (Tremfya), risankizumab (Skyrizi) and tildrakizumab (Ilumya), are injected monoclonal antibodies that bind the cytokine itself. Icotrokinra blocks the receptor instead, and it does so as a pill. The FDA approved Icotyde in March 2026 (Johnson & Johnson announced the decision on March 18) for moderate-to-severe plaque psoriasis in adults and in children 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The dose is one 200 mg tablet a day, taken on waking with water on an empty stomach, at least 30 minutes before food. The European Commission approval was announced on 21 September 2026. The drug was co-discovered by Protagonist Therapeutics and Johnson & Johnson under a collaboration that began in 2017; J&J develops and sells it. Why it matters beyond psoriasis: peptides make poor pills. A century of attempts using enteric coatings, enzyme inhibitors and absorption enhancers has mostly failed, and the best-known success, oral semaglutide, needs an absorption enhancer built into the tablet. Icotrokinra is engineered to survive digestion, works without an absorption enhancer, and binds its target so tightly (a dissociation constant of about 7 picomolar) that the tiny fraction absorbed is enough to block IL-23 signaling throughout the body. Johnson & Johnson is now testing it in psoriatic arthritis, ulcerative colitis and Crohn's disease, where injectable IL-23 blockers are already established. A note for people searching for 'icotrokinra peptide for sale': products sold online as research-chemical icotrokinra are not Icotyde. Nobody has verified what they contain, they are not made to pharmaceutical standards, and this is an immune-suppressing drug whose label calls for tuberculosis evaluation and infection monitoring.

What Icotrokinra Is Investigated For

Icotrokinra's evidence in plaque psoriasis is about as strong as a new drug's can be. Four Phase 3 trials with about 2,500 participants supported the approval. In ICONIC-LEAD (NEJM 2025; 684 adults and adolescents), 65% of people taking icotrokinra had clear or almost-clear skin (IGA 0/1) at week 16, against 8% on placebo, and 50% reached PASI 90. In ICONIC-ADVANCE 1 and 2 (Lancet 2025; 1,505 adults), it beat placebo and also beat deucravacitinib (Sotyktu), an established oral psoriasis drug. At week 16, IGA 0/1 was 68–71% with icotrokinra against 50–55% with deucravacitinib, and PASI 90 was 55–58% against 30–34%. ICONIC-TOTAL targeted the scalp, genitals, hands and feet, where psoriasis is hardest to treat. It met its primary endpoint and its scalp and genital endpoints. The hand-and-foot result at week 16 was not statistically significant, but clearance at all three sites kept improving with longer treatment. At the EADV congress in October 2026, Johnson & Johnson reported that 70% of ICONIC-TOTAL participants had clear or almost-clear skin at week 112. Complete clearance at that point was 60% for the scalp, 89% for the genitals and 63% for the hands and feet. In 16-week placebo-controlled data, side-effect rates were close to placebo. The honest caveats are these. No trial has compared icotrokinra directly with an injectable IL-23 antibody. An AbbVie-coauthored indirect comparison suggests risankizumab clears skin in more people (PASI 90 at week 16: about 71% against 50%). A head-to-head trial against ustekinumab (ICONIC-ASCEND) is still running. Ulcerative colitis has positive Phase 2b data. Psoriatic arthritis and Crohn's disease have Phase 3 trials enrolling but no efficacy results, so any use outside plaque psoriasis is investigational.

History & Discovery

Icotrokinra came out of Protagonist Therapeutics, a peptide drug company in Newark, California. In 2017 Janssen licensed Protagonist's first oral IL-23 receptor antagonist, PTG-200 (JNJ-67864238), which went into a Phase 2 trial in Crohn's disease, where a drug acting from inside the gut made obvious sense. In May 2019 the companies expanded the deal to cover second-generation compounds, and in 2020 they nominated two of them for clinical development. One, PN-235 (JNJ-77242113, often shortened to JNJ-2113), started its first human study in November 2020 and later received the international nonproprietary name icotrokinra. A 2024 paper in Scientific Reports by Johnson & Johnson and Protagonist scientists described its 7 pM affinity for IL-23R and its selectivity over IL-12 signaling. It also showed it could block IL-23 effects in skin and blood after oral dosing, not only in the gut. That systemic activity opened the way to psoriasis. The Phase 2b FRONTIER 1 trial (NEJM, February 2024) gave 255 people with moderate-to-severe psoriasis one of five doses or placebo, and found a clear dose response, with PASI 75 in 79% at the top dose. The Phase 3 ICONIC program started in October 2023 and January 2024. ICONIC-LEAD enrolled adults and adolescents against placebo. ICONIC-TOTAL focused on scalp, genital and hand/foot disease. ICONIC-ADVANCE 1 and 2 added deucravacitinib as an active comparator, a deliberate choice to test icotrokinra against the best existing targeted pill. Results appeared in the Lancet (September 2025), NEJM and NEJM Evidence (November 2025), and all four trials met their primary endpoints. The FDA approved Icotyde in March 2026 (announced March 18) for plaque psoriasis in adults and adolescents 12 and older weighing at least 40 kg. It was the first approval of an oral peptide that targets IL-23R. Protagonist has reported a China (NMPA) approval in August 2026. The European Commission approval followed a positive CHMP opinion and was announced on 21 September 2026. At the EADV congress on October 2, 2026, J&J reported ICONIC-TOTAL results through week 112: 70% of patients had clear or almost-clear skin, with complete clearance in 60% for the scalp, 89% for the genitals and 63% for the hands and feet. Development has now come back to the gut and extended to the joints. ANTHEM-UC, a Phase 2b ulcerative colitis trial, was positive in 2025, and ICONIC-UC (Phase 3), ICONIC-CD (Phase 2b/3 in Crohn's disease), ICONIC-PsA 1 and 2 (Phase 3 in psoriatic arthritis) and ICONIC-ASCEND (Phase 3, head to head with ustekinumab in psoriasis) are under way.

How It Works

Your immune system uses a messenger called IL-23 to keep a group of inflammatory T cells (Th17 cells) switched on. In psoriasis, this pathway runs too hot, and the IL-17 and IL-22 it produces keep the skin inflamed, building the thick, scaly plaques of the disease. Icotrokinra is a small ring-shaped peptide that sits in the IL-23 receptor, the 'lock' that IL-23 fits into, so IL-23 cannot get in and send its signal. Fewer IL-17 and IL-22 signals means the plaques settle down. The injected biologics Skyrizi and Tremfya mop up IL-23 itself. Icotrokinra blocks the receptor, and because it survives the stomach it can be taken as a pill.

IL-23 is a two-part cytokine. Its p40 subunit is shared with IL-12, while its p19 subunit is unique to IL-23, and it signals through a receptor that pairs IL-23R with the IL-12Rβ1 chain IL-12 also uses. IL-23 sits at the head of the IL-23/Th17 pathway, and blocking it lowers IL-17A, IL-17F and IL-22, the cytokines that keep psoriatic skin inflamed. Earlier drugs block this pathway at the cytokine. Ustekinumab binds p40 and so blocks both IL-12 and IL-23, while guselkumab, risankizumab and tildrakizumab bind p19 and block IL-23 alone. Guselkumab, risankizumab and ustekinumab are also approved for psoriatic arthritis, Crohn's disease and ulcerative colitis. Deucravacitinib works further downstream, inside the cell: it inhibits TYK2, a JAK-family enzyme that relays signals from several cytokine receptors, and lowers both IL-23-pathway and type I interferon-pathway gene activity in psoriatic skin. Icotrokinra binds IL-23R itself, with a dissociation constant of about 7 picomolar, and prevents IL-23 from engaging it. In human cell assays it blocked IL-23 signaling at a 5.6 pM half-maximal concentration without affecting IL-12 signaling (Fourie et al., Sci Rep 2024). The label reports drops in serum IL-17A, IL-17F, IL-19, IL-22 and β-defensin-2, and lower expression of Th17-pathway genes in lesional skin biopsies. Its pharmacology is unusual for a peptide pill. It peaks in the blood about 2 hours after a dose, has a half-life of about 12 hours and reaches steady state in about 3 days. In rats and monkeys, oral bioavailability was only 0.1–0.3%, with no absorption enhancer in the formulation. The drug is stable in gut fluids, and in people 37–81% of the dose passes out unchanged in the stool within 24 hours. Because the binding is so tight, the small absorbed fraction still blocks IL-23 in blood and skin; ex vivo IL-23 responses in whole blood were suppressed in healthy volunteers. Tissue studies found it in skin, joints and the gut wall. The high concentration in the gut lumen may help in inflammatory bowel disease, where oral icotrokinra also reduced inflammation in a rat colitis model. It is broken down into smaller peptides rather than by liver CYP enzymes, and it neither blocks nor is carried by the common drug transporters, which is why the label lists no clinically significant drug interactions.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Icotrokinra:

• 01No head-to-head trial against an injectable IL-23 antibody yet. An AbbVie-coauthored indirect comparison suggests risankizumab clears skin in more people, and ICONIC-ASCEND (versus ustekinumab) is the first direct comparison against an injectable.
• 02Psoriatic arthritis efficacy is unknown until ICONIC-PsA 1 and 2 report; clearing skin does not by itself show that joint inflammation will respond.
• 03Crohn's disease and ulcerative colitis. ANTHEM-UC was positive in Phase 2b, but Phase 3 ICONIC-UC and Phase 2b/3 ICONIC-CD will decide whether an oral IL-23R blocker can match injectable IL-23 antibodies in IBD, and whether its high gut-lumen exposure adds anything.
• 04Long-term safety beyond about two years, including rare serious infections, malignancy and effects in older adults and people with kidney impairment, will come from extension studies and post-marketing surveillance.
• 05Adherence in real life. A daily fasting-state pill with a 30-minute food wait is easy to take wrongly. How often real-world patients take it with food, and how much efficacy that costs, has not been measured.
• 06Pregnancy and breastfeeding outcomes, which are being followed in a pregnancy safety study.
• 07Whether the 'oral peptide that works despite near-zero absorption' design can be repeated for other cytokine receptors. Protagonist's oral IL-17 antagonist PN-881 is the next test, with Phase 2b planned for 2027.

Forms & Administration

Icotyde is a 200 mg film-coated oral tablet (yellowish orange to brown, debossed '200' and 'JNJ'). The label dose is one tablet once daily, taken on waking on an empty stomach with water, then waiting at least 30 minutes before eating. It should be swallowed whole, not crushed, split or chewed. People who have trouble swallowing tablets can disperse it in at least 120 mL (4 oz) of water, drink it within 15 minutes, then rinse the cup with another 120 mL and drink that too. A missed dose should be taken as soon as possible, with the usual schedule resuming the next day. It is a prescription medicine, normally started by a dermatologist after a TB assessment and a vaccination review. There is no injectable form and no generic version. Products sold as research-chemical 'icotrokinra' are not this product.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Icotyde is approved only for moderate-to-severe plaque psoriasis in people 12 and older weighing at least 40 kg. Use in psoriatic arthritis, ulcerative colitis, Crohn's disease or any other condition is investigational. Research-chemical 'icotrokinra' is unapproved, of unknown identity and purity, and should not be taken.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Icotrokinra Is NOT For

Drug & Supplement Interactions

The label reports no clinically significant drug interactions. No formal clinical interaction studies have been done, but in laboratory testing icotrokinra neither inhibits nor induces the major CYP450 enzymes, and it is neither a substrate nor an inhibitor of the common drug transporters (P-gp, BCRP, OATPs, OATs, OCT2, MATEs). It is broken down by ordinary peptide catabolism, not by the liver's drug-metabolizing enzymes, so classic metabolic interactions are not expected. The practical interactions are pharmacodynamic and timing-related. Food is the biggest factor: a high-fat meal cut exposure by 43%, which is why the label requires an empty stomach and a 30-minute wait. Whether other medicines swallowed at the same moment change icotrokinra's very small absorbed fraction has not been studied. Spacing other morning tablets until after the 30-minute window is a reasonable precaution to discuss with the prescriber. Combining icotrokinra with other systemic immunosuppressants or biologics was not studied in the psoriasis trials and could add to infection risk. Live vaccines should be avoided during treatment, and responses to inactivated vaccines have not been measured.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions